Sanofi US Launches Collaborative Activate Innovation Campaign
(3BL Media) Bridgewater, NJ – July 24, 2012 – Sanofi US launched the Collaborate Activate Innovation Challenge, which will award a total of $500,000 to teams of patient advocacy groups and/or medical professional associations who deliver novel approaches to better engage patients in their own health. Based on the concept that advocates working together can make a bigger collective impact than groups working alone, the Challenge requires groups to collaborate to qualify for the contest.
“To achieve successful health outcomes, the patient must be actively engaged in his or her own health," said Anne Whitaker, President North America Pharmaceuticals at Sanofi US. “With patients spending on average only a few hours in a doctor's office a year, successful management of any health condition goes beyond the physician and requires positive impact from the groups that support the patient - from caregivers to patient advocates to providers. Sanofi US is pleased to present the Collaborate Activate Innovation Challenge to promote collaboration between the key patient influencers to help identify new ways to encourage patient engagement, to help patients navigate their journey with their condition, and ultimately to improve the patients' health outcomes.”
The Innovation Challenge is designed to foster collaboration between non-profit organizations with a common purpose and promote sharing of complementary resources to accelerate the impact on people’s health. To support this idea, the entries must meet these parameters:
- Proposed ideas must focus on engaging people to take an active role in their healthcare
- Submissions must include two or more non-profit patient advocacy groups and/or medical professional organizations; a multidisciplinary approach is highly encouraged
Four finalist teams will receive opportunities for mentorship to fully optimize impact and outcomes. At a Finalist Event, the four teams will present their plans to a panel of expert judges and a winning team and runner-up will be selected.
The Collaborate Activate Innovation Challenge awards totalling $500,000 will be distributed as follows:
- Four finalist teams will be selected and will each receive $25,000
- From the four teams, one runner-up will receive an additional $100,000
- One winning team will receive an additional $300,000
Submissions will be accepted July 23 through August 31, 2012. Finalists will be announced on September 17 and the winner will be announced on November 15, 2012.
For a complete list of Challenge rules, and to submit a concept, visit: www.collaborateactivate.com.
To follow the Challenge as it progresses, follow us:
• Twitter: https://twitter.com/SanofiUS
• Facebook: https://www.facebook.com/sanofiUS
Sanofi US “Partners in Patient Health”
The Collaborate Activate Innovation Challenge is an initiative of Sanofi US’s Partners in Patient Health team, which is leading a novel approach to partnering with the advocacy community by connecting people, ideas, and solutions to focus on critical issues that are of high importance and common across a wide range of advocates dedicated to advancing patient health.
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Sanofi is the holding company of a consolidated group of subsidiaries and operates in the United States as Sanofi US. For more information on Sanofi US, please visit http://www.sanofi.us or call 1-800-981-2491.
-- # # # # --
Forward Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group’s ability to benefit from external growth opportunities as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2010. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.